Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;27(5):295–299. doi: 10.1002/clc.4960270512

Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study

Marius Berman 1,✉, Arie Erman 2, Tuvia Ben‐Gal 3, Dan Dvir 1, Georgios P Georghiou 1, Alon Stamler 1, Yaffa Vered 4, Bernardo A Vidne 1, Dan Aravot 1
PMCID: PMC6654743  PMID: 15188947

Abstract

Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.

Hypothesis: The purpose of the present double‐blind, placebo‐controlled, randomized study was to assess the effect of CoQ10 on patients with end‐stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.

Methods: A prospective double‐blind design was used. Thirty‐two patients with end‐stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome™‐‐‐CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6‐min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.

Results: Twenty‐seven patients completed the study. The study group showed significant improvement in the 6‐min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.

Conclusion: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end‐stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.

Keywords: coenzyme Q10, heart failure, heart transplantation

Full Text

The Full Text of this article is available as a PDF (61.1 KB).

References

  • 1. Lehnininger AI: Oxidation–reduction enzymes and electron transport In Biochemistry, 2nd edition, p. 493–497. New York: Worth Publishers, 1975. [Google Scholar]
  • 2. Lowe JS, Mortom RA, Vernon J: Unsaponifiable constituents of kidney in various species. Biochem J 1957; 67: 228–234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Cunningham NF, Morton RA: Unsaponifiable constituents of liver: Ubiquinone and substance SC in various species. Biochem J 1959; 72: 92–99 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Linn BO, Page AC, Wong EI Wong AL, Gale PH, Shunk GH, Folkers K: Isolation and distribution of coenzyme Q10 in animal tissues. Am Chem Soc 1959; 81: 4007–4010 [Google Scholar]
  • 5. Crane FL, Hatefi Y, Lester RL, Widmer G: Isolation of a quinone from beef heart mitochondria . Biochem Biophys Acta 1957; 25: 220–221 [DOI] [PubMed] [Google Scholar]
  • 6. King TE: Ubiquinone proteins and cardiac mitochondria In Function of Quinones in Energy Conserving Systems (Ed. Trumpower BL.), p. 3–25. New York: Academic Press, 1982. [Google Scholar]
  • 7. Folkers K, Littaru GP, Ho L, Runge TM, Havanonda S, Cooley D: Evidence for a deficiency of coenzyme Q10 in human heart disease. Int J Vitamin Res 1970; 40: 380–390 [PubMed] [Google Scholar]
  • 8. Littaru GP, Ho L, Folkers K: Deficiency of coenzyme Q10 in human heart disease, Part 1. Int J Vitamin Res 1972; 42: 291–305 [PubMed] [Google Scholar]
  • 9. Littaru GP, Ho L, Folkers K: Deficiency of coenzyme Q10 in human heart disease, Part 2. Int J Vitamin Res 1972; 42: 413–434 [PubMed] [Google Scholar]
  • 10. Mortensen SA: Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Invest 1993; 71S: 116–123 [DOI] [PubMed] [Google Scholar]
  • 11. Folkers K, Baker L, Richardson PC, Shizukuishi S, Takamura K, Drzewoski J, Lewandowski J, Ellis JM: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 2 (Eds. Yamamura Y, Folkers K, Ito Y.), p. 449 Amsterdam: Elsevier/North Holland, 1980. [Google Scholar]
  • 12. Yamamura Y, Ishiyama T, Yamogami T, Morita Y, Ishio I, Kashiwamura S, Terader A, Tsukamoto N, Toyama S, Nakajima Y, Wada N: Clinical use of coenzyme Q for treatment of cardiovascular disease. Jpn Circ J 1967; 31: 168–169 [Google Scholar]
  • 13. Yamamura Y: A survey of the therapeutic uses of coenzyme Q10 In Coenzyme Q Biochemisty, Bioenergetics and Clinical Applications of Ubiquinone (Ed. Lenaz G.), p. 479–507. New York: Wiley‐Interscience, 1985. [Google Scholar]
  • 14. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K: Long‐term coenzyme Q10 therapy: A major advance in the management of resistant myocardial failure. Drug Exp Clin Res 1985; 8: 581–593 [PubMed] [Google Scholar]
  • 15. Langsjoen PH, Vadhanavikit S, Folkers K: Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drug Exp Clin Res 1985; 8: 577–579 [PubMed] [Google Scholar]
  • 16. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G: Italian multi‐center study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Molec Aspects Med 1994; 15s: 287–294 [DOI] [PubMed] [Google Scholar]
  • 17. Hofman‐Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H: Coenzyme Q10 as an adjunctive in treatment of congestive heart failure. The Q10 study group. J Cardiac Fail 1995; 1 (2): 101–107 [DOI] [PubMed] [Google Scholar]
  • 18. Folkers K, Langsjoen P, Langsjoen PH: Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Comm 1992; 182: 247–253 [DOI] [PubMed] [Google Scholar]
  • 19. Rector J, Cohn JN: Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire—Reliability and validity during a randomized, double‐blind, placebo‐controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992; 124: 1017–1025 [DOI] [PubMed] [Google Scholar]
  • 20. Grossi G, Bargossi AM, Fiorella PL, Piazzi S: Improved high‐performance liquid chromatographic method for the determination of coenzyme Q10 in plasma. J Chromat 1992; 593: 217–226 [DOI] [PubMed] [Google Scholar]
  • 21. Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K: Usefulness of coenzyme Q10 in clinical cardiology: A long term study. Molec Aspects Med 1994; 15: 165–175 [DOI] [PubMed] [Google Scholar]
  • 22. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H: Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990; 87: 8931–8934 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Langsjoen PH, Vadhanavikit S, Folkers K: Response of patients in classes 3 and 4 of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82: 4240–4244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Digiesi V, Cantini F, Brodbeck B: Effect of coenzyme Q10 on essential arterial hypertension. Curr Ther Res Clin Exp 1990; 47: 841–845 [Google Scholar]
  • 25. Mortensen SA: Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 304–305 [DOI] [PubMed] [Google Scholar]
  • 26. Morisco C, Trimarco B, Condorelli M: Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long‐term multicenter randomized study. Clin Invest 1993; 71 (8 suppl): s134–136 [DOI] [PubMed] [Google Scholar]
  • 27. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN: Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999; 33: 1549–1552 [DOI] [PubMed] [Google Scholar]
  • 28. Boland DJ, Abraham WT: Natriuretic peptides in heart failure. Cong Heart Fail 1998; 4: 23–33 [Google Scholar]
  • 29. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K: Localisation and mechanism of secretion of B‐type natriuretic pep tide in comparison with those of A‐type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195–203 [DOI] [PubMed] [Google Scholar]
  • 30. Kim JK, Summer SN, Durr J, Schrier RW: Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. Kidney Int 1989; 35: 799–805 [DOI] [PubMed] [Google Scholar]
  • 31. Steele IC, McDowell G, Moore A, Campbell NP, Shaw C, Buchanan KD, Nicholls DP: Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal control subjects. Eur J Clin Invest 1997; 27: 270–276 [DOI] [PubMed] [Google Scholar]
  • 32. Zhao SP, Zeng LF: Elevated plasma levels of tumor necrosing factor in chronic heart failure with cachexia. Int J Cardiol 1997; 58: 257–261 [DOI] [PubMed] [Google Scholar]
  • 33. Milani RV, Mehra MR, Endres S, Eigler A, Cooper ES, Lavie CJ Jr, Ventura HO: The clinical relevance of circulating tumor necrosis factor alpha in acute decompensated chronic heart failure without cachexia. Chest 1996; 110 (4): 992–995 [DOI] [PubMed] [Google Scholar]
  • 34. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole‐Wilson PA, Coats AJ: Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79 (10): 1426–1430 [DOI] [PubMed] [Google Scholar]
  • 35. Landbo C, Almdal TP: Interaction between warfarin and coenzyme Q10. Ugeskr Laeger 1998; 160: 3226–3227 [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES